Actively Recruiting
Phase 2 Study of SHR-A1904 Treatment in Adults with Advanced or Metastatic Biliary Tract Cancer Positive for CLDN18.2 After Previous Systemic Therapy Failure
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-03-31
151
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating SHR-A1904 in a Phase 2 clinical trial for patients with advanced or metastatic biliary tract cancer who have previously received systemic treatment without success. The study aims to assess the drugs safety, effectiveness, how the body processes it, and the immune response it triggers. This trial focuses on patients with cancer expressing CLDN18.2 who have measurable tumors and a reasonable life expectancy. Participants will receive SHR-A1904 injections in either a low-dose or high-dose group. Treatment continues until the cancer worsens or side effects become unacceptable. The study is randomized without masking, meaning patients are assigned to one of the two dose groups openly. The treatment period may last up to about one year, with ongoing safety and immune monitoring. During the trial, participants will undergo regular assessments to measure tumor response, control of disease, time until response, and survival outcomes. Safety is monitored continuously by tracking adverse events and serious side effects. Immunogenicity tests will check for antibodies against SHR-A1904 for up to six months. Follow-up includes evaluation of overall survival for about two years, ensuring comprehensive monitoring of treatment effects and patient well-being throughout the study.
CONDITIONS
Brief Title
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Research Team
H
Haoyang Xin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here